Answers are grounded in this paper and cite their sources.
: Anti-CD38 antibody (Ab) is a human monoclonal antibody for the treatment of multiple myeloma. CD38 is ex-pressed on red blood cells (RBCs), and can interfere with pretransfusion tests. Here, we conducted a nation-wide multi-institutional collaborative study to clarify the interference of anti-CD38 Ab in pretransfusion tests, and investigated the current situation regarding the preparation of RBCs for patients who are treated with anti-CD38 Ab, as well as communication between clinicians and transfusion units on anti-CD38 therapy. anti-CD38 therapy was provided from clinicians to the transfusion units before pretransfusion tests in 116 cases (85%). In 3 cases, pan-agglutination was observed on Ab screening by the saline method using dithiothreitol (DTT)-treated RBCs, but not observed using DTT-untreated RBCs. In 6 cases, pan-agglutination was observed in Ab screening by the enzyme method after the receipt of anti-CD38 Ab, but not observed before receipt. RBCs were trans-fused in 65 cases after receiving anti-CD38 Ab. Adverse reactions did not occur in any case. Median time of a clinically relevant delay due to anti-CD38 Ab was 60 minutes (range, 45 minutes-24 hours). Given the increasing use of therapeu-tic monoclonal Abs for the treatment of cancer and other conditions, unexpected results in pretransfusion tests may become more commonplace.
No takes yet. Share an insight, caveat, or question.
Yamada et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: